Why:
- Moat: it resells forensic kit on non-exclusive dealerships into price-decided tenders. One supplier is now 41% of everything it buys, up from 12.5% two years ago, and the filing registers no patent and no trademark (T1). Rivals sell the same OEM brands into the same tenders, and its own OEMs run competing Indian channels (T3).
- Runway: the funded schemes the filing names add up to roughly ₹900 crore a year, and Kwick already takes about a tenth of that. The ₹30,000 crore headline it leans on is a ministerial statement with no budget behind it, and the largest named scheme lapsed in FY2026 with its successor not yet approved (T3).
- Offer: about half the fresh issue quietly frees up cash for uses the filing never names. The stated object is working capital, but the projection cuts the company's own funding of it so that ₹23 crore of internal money is released with no stated destination (T1).
Valuation at the band
| Floor ₹85 (T1) | Cap ₹90 (T1) | |
|---|---|---|
| Bid window | 27 to 31 August 2026 | |
| Bid lot | 1,600 shares | |
| Fresh issue proceeds | ₹39 cr | ₹41 cr |
| Post-issue shares | 2,14,36,440 | 2,14,36,440 |
| Market capitalisation | ₹182 cr | ₹193 cr |
| P/E on FY2026 profit | 13.5x | 14.3x |
| EV/EBITDA (company holds net cash) | 8.9x | 9.5x |
| Promoter holding after | 56.4% | 56.4% |
The filing names no listed peers at all, so there is no issuer-chosen peer P/E to compare these multiples against. The price does not move the verdict either way; the six ratings judge the business, not the band.
The story
A Chennai forensic-equipment house riding India's new criminal codes, which make forensic examination compulsory for serious offences. Revenue tripled to ₹106 crore in two years selling crime-scene kit, kitted vans and cyber-forensics tools to police forces and forensic labs. The execution is real; the business underneath is a tender-won dealership.
What this business is
Kwick supplies forensic science equipment to Indian police forces and forensic science laboratories. It sells evidence-collection kits and lab instruments, fits out mobile crime-scene-investigation vehicles, supplies cyber and digital forensics tools, sells DNA-analysis equipment, and rents forensic equipment with trained manpower. Most of what it sells is bought from global equipment makers such as Sirchie, Thermo Fisher and Rapiscan under non-exclusive dealership arrangements, won through government tenders, increasingly on the GeM portal. It has one in-house product line of note, a crime-scene virtual-reality trainer co-developed with the Home Ministry's forensic directorate.
The buyer base is concentrated and public: the top customer is 24% of revenue and the top ten are 78%. A single rental contract with one state supplies roughly 9% of revenue at very high margin. In FY2026 growth broadened beyond government: non-government buyers supplied most of the year's increase, which the filing discloses but does not explain.
Easy or difficult business? Run-of-the-mill, done competently. Winning a forensic tender needs OEM authorisation letters, a service presence and tender experience, which keeps casual entrants out but not the other authorised dealers of the same brands. The one genuinely hard piece, its own devices and software, employs four of its 45 people.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 30.2 | 65.0 | 105.7 |
| Revenue growth % | n/a | 115.4 | 62.6 |
| Gross margin % | 37.3 | 31.2 | 27.1 |
| EBITDA | 5.4 | 12.2 | 19.0 |
| EBITDA margin % | 17.8 | 18.8 | 17.9 |
| PAT | 2.8 | 8.6 | 13.5 |
| PAT growth % | n/a | 202.0 | 57.8 |
The gross-margin fall looks like decay and is mostly a completed reset: the company moved from imported to domestic sourcing (imports fell from 35% to 9% of purchases) and let its highest-margin rental line shrink as a share of the mix. At constant mix, margins were flat. Profit growth outran revenue because a fixed cost base of 45 people was spread over 3.5x the revenue.
| Segment, ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Forensic science and physical evidence | 11.8 | 18.6 | 39.1 |
| Forensic science growth % | n/a | 57.7 | 110.3 |
| Cyber and digital forensics | 6.4 | 15.1 | 35.2 |
| Cyber growth % | n/a | 134.6 | 133.7 |
| Mobile CSI vehicles | 4.1 | 16.4 | 10.6 |
| Mobile CSI growth % | n/a | 305.0 | -35.6 |
| DNA forensics | 0.4 | 6.2 | 11.4 |
| DNA growth % | n/a | 1,343.4 | 84.8 |
| Equipment rental | 6.7 | 8.4 | 9.3 |
| Rental growth % | n/a | 25.1 | 10.2 |
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | The channel is real but replicable. Twenty years of agency relationships, tender qualifications and a service network won this business 3.5x growth, two-to-eight states above ₹5 crore, and an MHA technology-challenge win. But the dealerships are non-exclusive, the same OEMs run other Indian channels, one supplier is 41% of purchases, no IP is registered, and tenders are decided on price against a standard government specification. Revealed performance earns the middle grade; nothing defends it. |
| Industry and TAM | MARGINAL | The statutory demand is real; the funded, named pool is ~₹900 cr a year and Kwick already holds ~12% of it. The bigger headline number has no appropriation behind it. |
| Financial momentum | PASS | Revenue 3.5x and profit 4.8x in two years, debt-free with ₹13 cr net cash, working-capital cycle improving, and the margin fall a completed sourcing reset rather than a trend. |
| Risks, governance, RPTs | PASS | Clean where it matters: no fraud, no pledge, no promoter loans out, tiny litigation; the hygiene lapses are small and disclosed. |
| Promoter and cap table | MARGINAL | One strong leg (the scaling arc) against prior ventures that never scaled, placement paper 40% churned before listing, and free shares gifted to a person who became CFO seven months later. |
| Offer structure | MARGINAL | Fresh-heavy and debt-free, but the working-capital ask releases ₹23 crore of internal funding to no named use, unappraised and unmonitored. |
Watch out for
- ₹1.2 crore of shares was gifted, free, to a person who became the company's CFO seven months later (T1). Disclosed, legal, and unexplained.
- The top supplier is 41% of purchases on a non-exclusive arrangement (T1). A terms change there lands straight on a 27% gross margin.
- The scheme funding the largest identified forensic pool lapsed in FY2026; its successor was still awaiting approval at the filing date (T3).
The offer
- Raising up to ₹51 crore at the cap: ₹41 crore fresh and ₹10 crore offer for sale by the three promoters (T1).
- For working capital (₹31 crore) and general corporate purposes; no debt to repay and no capex object.
- Implied valuation ₹182 to ₹193 crore, from the table above.
- Promoters hold 78.1% before the offer and 56.4% after, selling 8.2% of their own holding in the offer for sale (T1).
Initial assessment from the RHP only, with no outside verification beyond the price band and offer dates, which come from the BSE public records, and a bounded outside check on the demand-pool and competition claims, tiered where cited. Numbers carry source tiers: (T1) the filing's audited sections, (T3) the issuer-commissioned industry chapter or press sources, UNVERIFIED where nothing supports them. Not a recommendation. The valuation section states what the announced band implies and is not a view on whether that price is right.